Share Purchase Plan
Released
Released
Announcement PDF
Share Purchase Plan
Melbourne, Australia; 28 October 2014: Starpharma Holdings Ltd (ASX: SPL, OTCQX:
SPHRY) advises that its share purchase plan (SPP) will close at 5pm (Melbourne time)
tomorrow, Wednesday 29 October 2014.
Eligible shareholders are entitled to apply for up to a maximum value of A$15,000 per
shareholder under the SPP at an issue price of A$0.65 per share.
The non-underwritten SPP will be capped at $5 million. Applications have been received to
date for more than 65% of this amount and as outlined in the SPP offer documents,
Starpharma may choose to place any shortfall from the SPP with institutional, sophisticated
and professional investors. If it does so, the issue price for the shortfall will be no less than
$0.65.
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a
world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular
in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development
programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products
internally and others via commercial partnerships.
Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which is a
potent microbicidal agent. VivaGel® formulated as a water based gel and delivered vaginally is under clinical development
for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate licence agreements
with Ansell Limited (ASX:ANN) and Okamoto Industries. Inc., (TSE: JP3192800005) to market a value-added, VivaGel®
condom. Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom
market. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®.
In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery.
Drug Delivery partners include GSK, Lilly and AstraZeneca. A number of dendrimer-enhanced, or DEP™ versions of
existing drugs are under development. The most advanced of these is DEP™docetaxel, a dendrimer-enhanced version of
docetaxel (Taxotere®), which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant
tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung
and ovarian tumour, when compared to Taxotere® (docetaxel).
In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama
(formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient
in Roundup®).
Media:
Buchan Consulting
Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au
Starpharma:
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
www.starpharma.com
Gabriella Hold
+61 3 9866 4722
ghold@buchanwe.com.au
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of
forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”,
“targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or
similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of
product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding
any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for
sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval
and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain
or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial
results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is
providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or developments or otherwise.
Page 2 of 2
Share your feedback
Discover